Actively Recruiting
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Led by Yale University · Updated on 2025-05-31
105
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
Y
Yale University
Lead Sponsor
N
National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
CONDITIONS
Official Title
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female subjects aged 18 to less than 90 years
- Able to understand and provide informed consent before study procedures
- Must be in good health
You will not qualify if you...
- Under 18 years of age
- Pregnant or breastfeeding
- Any significant systemic illness or unstable medical condition
- Pre-existing medical conditions or claustrophobic reactions
- Research-related radiation exposure exceeding 50 mSv in the prior 12 months
- History of bleeding disorders or currently taking anticoagulants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yale University PET Center
New Haven, Connecticut, United States, 06510
Actively Recruiting
Research Team
S
Shannan Henry
CONTACT
K
Kayla Cottiers
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here